Cargando…
The new K(V)3.4 inhibitor BDS-I[1–8] as a potential pharmacological opportunity in Alzheimer’s disease therapy
Autores principales: | Piccialli, Ilaria, Ciccone, Roselia, Pannaccione, Anna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7047807/ https://www.ncbi.nlm.nih.gov/pubmed/31960809 http://dx.doi.org/10.4103/1673-5374.272580 |
Ejemplares similares
-
Synthesis and Pharmacological Evaluation of a Novel Peptide Based on Anemonia sulcata BDS-I Toxin as a New K(V)3.4 Inhibitor Exerting a Neuroprotective Effect Against Amyloid-β Peptide
por: Ciccone, Roselia, et al.
Publicado: (2019) -
The Anemonia sulcata Toxin BDS-I Protects Astrocytes Exposed to Aβ(1–42) Oligomers by Restoring [Ca(2+)](i) Transients and ER Ca(2+) Signaling
por: Piccialli, Ilaria, et al.
Publicado: (2020) -
Exploring the Therapeutic Potential of Phytochemicals in Alzheimer’s Disease: Focus on Polyphenols and Monoterpenes
por: Piccialli, Ilaria, et al.
Publicado: (2022) -
The Na(+)/Ca(2+) Exchanger 3 Is Functionally Coupled With the Na(V)1.6 Voltage-Gated Channel and Promotes an Endoplasmic Reticulum Ca(2+) Refilling in a Transgenic Model of Alzheimer’s Disease
por: Piccialli, Ilaria, et al.
Publicado: (2021) -
Amyloid β-Induced Upregulation of Na(v)1.6 Underlies Neuronal Hyperactivity in Tg2576 Alzheimer’s Disease Mouse Model
por: Ciccone, Roselia, et al.
Publicado: (2019)